Glaukos Corporation (GKOS) Cut to “Sell” at BidaskClub
BidaskClub lowered shares of Glaukos Corporation (NYSE:GKOS) from a hold rating to a sell rating in a research report report published on Saturday.
Several other brokerages also recently weighed in on GKOS. Zacks Investment Research downgraded Glaukos Corporation from a hold rating to a sell rating in a report on Tuesday, May 2nd. Cantor Fitzgerald reissued an overweight rating and issued a $54.00 price target on shares of Glaukos Corporation in a report on Thursday, May 4th. TheStreet downgraded Glaukos Corporation from a c rating to a d+ rating in a report on Wednesday, May 3rd. Stephens raised Glaukos Corporation from an equal weight rating to an overweight rating in a report on Monday, May 8th. Finally, Piper Jaffray Companies reissued a buy rating and issued a $56.00 price target on shares of Glaukos Corporation in a report on Thursday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $52.33.
Shares of Glaukos Corporation (NYSE:GKOS) opened at 36.51 on Friday. Glaukos Corporation has a one year low of $28.72 and a one year high of $52.49. The stock has a 50 day moving average of $38.96 and a 200 day moving average of $42.96. The stock’s market cap is $1.26 billion.
WARNING: “Glaukos Corporation (GKOS) Cut to “Sell” at BidaskClub” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/glaukos-corporation-gkos-cut-to-sell-at-bidaskclub/1528919.html.
In other Glaukos Corporation news, Director Orbimed Advisors Llc sold 325,000 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was sold at an average price of $37.93, for a total value of $12,327,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 16.40% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP purchased a new stake in Glaukos Corporation during the first quarter worth approximately $372,000. William Blair Investment Management LLC increased its stake in Glaukos Corporation by 5.3% in the first quarter. William Blair Investment Management LLC now owns 2,064,444 shares of the medical instruments supplier’s stock worth $105,906,000 after buying an additional 104,670 shares during the period. Teachers Advisors LLC increased its stake in Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock worth $953,000 after buying an additional 1,506 shares during the period. Parametric Portfolio Associates LLC increased its stake in Glaukos Corporation by 39.1% in the first quarter. Parametric Portfolio Associates LLC now owns 61,561 shares of the medical instruments supplier’s stock worth $3,158,000 after buying an additional 17,313 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Glaukos Corporation by 43.6% in the first quarter. Alliancebernstein L.P. now owns 1,291,882 shares of the medical instruments supplier’s stock worth $66,274,000 after buying an additional 392,476 shares during the period.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.